Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 nov. 2022 09h15 HE | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc....
25 oct. 2022 09h15 HE | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.

SEATTLE, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
24 oct. 2022 09h15 HE | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

SEATTLE, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
07 sept. 2022 09h00 HE | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
22 août 2022 09h30 HE | Source: Atossa Therapeutics, Inc.

Registration Now Open for Tribe Public’s Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022

SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant...
18 août 2022 09h30 HE | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
08 août 2022 16h30 HE | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...
28 juil. 2022 09h00 HE | Source: Atossa Therapeutics, Inc.

Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
02 juin 2022 16h05 HE | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of...
18 mai 2022 09h30 HE | Source: Atossa Therapeutics, Inc.

Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of...

Page précédente

Page suivante